Cellcept and Raynaud's phenomenon - a phase IV clinical study of FDA data

Summary:

Raynaud's phenomenon is reported as a side effect among people who take Cellcept (mycophenolate mofetil), especially for people who are female, 50-59 old, have been taking the drug for 6 - 12 months also take Rituxan, and have Systemic sclerosis (scleroderma).

The phase IV clinical study analyzes which people have Raynaud's phenomenon when taking Cellcept. It is created by eHealthMe based on reports of 41,092 people who have side effects when taking Cellcept from the FDA, and is updated regularly.

What is Cellcept?

Cellcept has active ingredients of mycophenolate mofetil. It is often used in systemic lupus erythematosus. eHealthMe is studying from 41,872 Cellcept users. Check the latest studies of Cellcept.

What is Raynaud's phenomenon?

Raynaud's phenomenon (discoloration of the fingers, toes, and occasionally other areas) is found to be associated with 635 drugs and 995 conditions by eHealthMe. Check the latest studies of Raynaud's phenomenon.

On Apr, 10, 2026

41,092 people reported to have side effects when taking Cellcept.
Among them, 63 people (0.15%) have Raynaud's phenomenon.

Could Cellcept cause Raynaud's phenomenon?

Among these 63 people:

How long have people been on Cellcept when they have Raynaud's phenomenon? *

What is the gender of people who have Raynaud's phenomenon when taking Cellcept? *

female: 71.93 %
male: 28.07 %

What is the age of people who have Raynaud's phenomenon when taking Cellcept? *

What are other drugs people take besides Cellcept? *

What are other side effects people have besides Raynaud's phenomenon? *

Fatigue (feeling of tiredness): 26 people, 41.27%
Joint Pain: 20 people, 31.75%
Nausea (feeling of having an urge to vomit): 19 people, 30.16%
Dyspnea (difficult or laboured breathing): 19 people, 30.16%
Headache (pain in head): 17 people, 26.98%
Diarrhea: 16 people, 25.40%
Weight Decreased: 16 people, 25.40%
Malaise (a feeling of general discomfort or uneasiness): 15 people, 23.81%
Skin Discoloration: 14 people, 22.22%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 14 people, 22.22%

What are the existing conditions these people have? *

Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 12 people, 19.05%
Interstitial Lung Disease: 10 people, 15.87%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 9 people, 14.29%
Pain: 6 people, 9.52%
Idiopathic Pulmonary Fibrosis (chronic lung disease): 5 people, 7.94%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 5 people, 7.94%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 5 people, 7.94%
High Blood Pressure: 4 people, 6.35%
Central Nervous System Inflammation (infection of brain or spinal cord): 3 people, 4.76%
Cough: 3 people, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Cellcept and have Raynaud's phenomenon?

- Check whether Raynaud's phenomenon is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cellcept:

Cellcept (41,872 reports)

Browse all side effects of Cellcept:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Raynaud's phenomenon:

Raynaud's phenomenon (635 drugs)

Browse all the conditions that are associated with Raynaud's phenomenon:

Raynaud's phenomenon (995 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on mycophenolate mofetil (the active ingredients of Cellcept) and Cellcept (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.